- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05263219
DEB-TACE+HAIC vs. HAIC for Large HCC
Transarterial Chemoembolization With Drug-eluting Beads Plus Hepatic Arterial Infusion Chemotherapy Versus Hepatic Arterial Infusion Chemotherapy Alone for Large Hepatocellular Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, prospective and randomized study to evaluate the efficacy and safety of DEB-TACE (with CalliSpheres) plus HAIC compared with HAIC alone for unresectable large HCC (>7cm).
230 patients with initially unresectable large HCC (> 7cm) will be enrolled in this study. The patients will receive either DEB-TACE plus HAIC (dTACE-HAIC) or HAIC as the primary treatment using an 1:1 randomization scheme. In the dTACE-HAIC arm, the microcatheter will be reserved at the proper/left/right hepatic artery and chemotherapy drugs (FOLFOX-based regimen) will be intra-arterially administered though the microcatheter. The treatment can be repeated on demand (at a 4-6-week interval usually) based on the evaluation of follow-up laboratory and imaging examination by the multidisciplinary team. In the HAIC arm, treatment will repeated once every 3 weeks for up to six cycles. During follow-up, the potential resectability of the tumor will be assessed by the multidisciplinary team (MDT). Once the tumors become resectable, curative surgical resection will be recommended for the patients.
The primary end point of this study is overall survival (OS). The secondary endpoints are tumor response (objective response rate and disease control rate), success rate of conversion to resection, progression-free survival (PFS), and adverse events (AEs).
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Mingyue Cai, Dr.
- Phone Number: +86-20-34156205
- Email: cai020@yeah.net
Study Contact Backup
- Name: Kangshun Zhu, Dr.
- Phone Number: +86-20-34156205
- Email: zhksh010@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510260
- Recruiting
- The Second Affiliated Hospital of Guangzhou Medical University
-
Contact:
- Mingyue Cai, Dr.
- Phone Number: +86-20-34156205
- Email: cai020@yeah.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with HCC confirmed by histology/cytology or diagnosed clinically.
- The maximum HCC lesion > 7 cm.
- Unresectable HCC evaluated by the surgeon team.
- At least one measurable intrahepatic target lesion.
- Patients without cirrhosis, or with cirrhosis but the liver function of Child-Pugh Class A.
- ECOG score of performance status ≤ 1 point.
- Adequate organ and bone marrow function; the blood biochemical examination: platelet count ≥75×10^9/L, leukocyte >3.0×10^9/L, ASL and AST≤5×ULN, creatinine≤1.5×ULN, INR<1.5 or PT/APTT normal range.
- Life expectancy of at least 3 months.
Exclusion Criteria:
- Accompanied with tumor thrombus involving the main portal vein or bilateral first-order branch of portal vein.
- Accompanied with vena cava tumor thrombus.
- Extrahepatic metastasis.
- Previous treatment with TACE, HAIC, liver transplantation, resection, ablation, radiotherapy, or systemic therapy.
- Decompensated liver function, including: ascites, bleeding from gastroesophageal varices, and hepatic encephalopathy.
- Those with organs (heart and kidneys) dysfunction who cannot tolerate TACE or HAIC treatment.
- History of other malignancies.
- Uncontrollable infection.
- History of HIV.
- Allergic to the drugs involved in the research.
- Patients with gastrointestinal bleeding within 30 days, or other bleeding> CTCAE grade 3.
- History of organ or cells transplantation.
- Those with bleeding tendency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transarterial chemoembolization with drug-eluting beads plus hepatic arterial infusion chemotherapy
Patients will receive the combination treatment of DEB-TACE and HAIC.
|
For DEB-TACE, superselective catheterization is performed and CalliSpheres loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In patients with huge or bilobar multiple lesions, in order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. After each chemoembolization, the microcatheter is reserved at the proper/left/right hepatic artery. The FOLFOX-based regimen is intra-arterially administered. During follow-up, the treatment will be repeated on demand (at a 4-6-week interval usually) based on the evaluation of the follow-up laboratory and imaging examination. CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected. FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
Other Names:
|
Active Comparator: Hepatic arterial infusion chemotherapy
Patients will receive HAIC treatment alone.
|
HAIC treatment is divided into 3-week cycles. The microcatheter is advanced into the proper/left/right hepatic artery on day 1 in every cycle of treatment. After the patient returned to the ward, the FOLFOX-based regimen is intra-arterially administered though the microcatheter. The treatment is repeated once every 3 weeks for up to six cycles.
FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: 4 years.
|
The time from date of randomization to death due to any cause.
|
4 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR) per mRECIST.
Time Frame: 4 years.
|
The proportion of patients with the best response of complete response (CR) or partial response (PR) according to mRECIST.
|
4 years.
|
ORR per RECIST 1.1.
Time Frame: 4 years.
|
The proportion of patients with the best response of CR or PR according to RECIST 1.1.
|
4 years.
|
Disease control rate (DCR) per mRECIST.
Time Frame: 4 years.
|
The proportion of patients with the best response of CR, PR, or stable disease (SD) according to mRECIST.
|
4 years.
|
DCR per RECIST 1.1.
Time Frame: 4 years.
|
The proportion of patients with the best response of CR, PR, or SD according to RECIST 1.1.
|
4 years.
|
Progression free survival (PFS) per mRECIST.
Time Frame: 4 years.
|
The time from date of randomization until the first occurrence of disease progression (according to mRECIST) or death due to any cause, whichever occurs first.
|
4 years.
|
Progression free survival (PFS) per RECIST 1.1.
Time Frame: 4 years.
|
The time from date of randomization until the first occurrence of disease progression (according to RECIST 1.1) or death due to any cause, whichever occurs first.
|
4 years.
|
Success rate of conversion to resection
Time Frame: 4 years.
|
The proportion of patients with initially unresectable large HCC who were evaluated by the surgical team as suitable for surgical resection after dTACE-HAIC or HAIC treatment.
|
4 years.
|
Adverse Events (AEs)
Time Frame: 4 years.
|
Number of patients with AEs assessed by Common Terminology Criteria for Adverse Events v5.0.
|
4 years.
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Kangshun Zhu, Dr., Second Affiliated Hospital of Guangzhou Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MIIR-09
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unresectable Hepatocellular Carcinoma
-
National Cancer Institute (NCI)Active, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Hepatocellular Carcinoma | Metastatic Cholangiocarcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular... and other conditionsUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteNational Comprehensive Cancer NetworkWithdrawnLiver Cancer | HepatoCellular Carcinoma | Unresectable HepatoCellular CarcinomaUnited States
-
BeiGeneCompletedHepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Metastatic Hepatocellular CarcinomaChina
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic CholangiocarcinomaUnited States
-
Mayo ClinicRecruitingAdvanced Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8United States
-
Sirtex MedicalBright Research PartnersRecruitingUnresectable Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Sun Yat-sen UniversityXiangya Hospital of Central South University; Nanfang Hospital of Southern... and other collaboratorsRecruitingUnresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma by BCLC StageChina
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnUnresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
-
Wen LiRecruitingUnresectable Hepatocellular CarcinomaChina
-
Yue HanJiangsu HengRui Medicine Co., Ltd.RecruitingHAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE FailureUnresectable Hepatocellular CarcinomaChina
Clinical Trials on dTACE-HAIC
-
Sun Yat-sen UniversityRecruitingHepatocellular Carcinoma | Potentially ResectionChina
-
Shandong Cancer Hospital and InstituteRecruitingIntrahepatic CholangiocarcinomaChina
-
Fudan UniversityRecruiting
-
Peking University Cancer Hospital & InstituteRecruitingAdvanced Hepatocellular Carcinoma (HCC)China
-
Zhongda HospitalRecruiting
-
Peking University Cancer Hospital & InstituteUnknownHepatocellular Carcinoma | Transarterial Chemoembolization
-
Tianjin Medical University Cancer Institute and...Not yet recruitingIntrahepatic CholangiocarcinomaChina
-
Fudan UniversityRecruitingIntrahepatic CholangiocarcinomaChina
-
Tianjin Medical University Cancer Institute and...Not yet recruitingIntrahepatic CholangiocarcinomaChina
-
Yue HanJiangsu HengRui Medicine Co., Ltd.RecruitingHAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE FailureUnresectable Hepatocellular CarcinomaChina